Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Go back to Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration| (NASDAQ: OCGN) | Delayed: 1.04 +0.01 (0.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.03 | 52 Week High | $ | |||
| Open | $1.05 | 52 Week Low | $ | |||
| Day High | $1.08 | P/E | N/A | |||
| Day Low | $1.03 | EPS | $ | |||
| Volume | 5,713,268 | |||||
